Sarcomas | Specialty

LOXO-195 Active After Initial Anti-TRK Failure in Multiple Tumor Types

April 2nd 2019

A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.

When a Measure of Significance Is Not All That Significant

March 20th 2019

The term statistically significant is almost certainly beautiful music to the ears of clinical investigators and pharma/biotech companies. However, concern develops when one inquires how the most common test of significance, the P value, is used in clinical investigative efforts and whether at times this is more harmful than helpful within the domain of cancer medicine.

Dr. Ganjoo on the Treatment of Metastatic Uterine Leiomyosarcoma

February 21st 2019

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with metastatic uterine leiomyosarcoma.

Dr. George Discusses Ongoing Trials in Soft Tissue Sarcoma

February 12th 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).

FDA Grants Priority Review to Pexidartinib for Tenosynovial Giant Cell Tumor

February 6th 2019

The FDA has granted a priority review designation to a new drug application for the investigational, small molecule, CSF1R receptor inhibitor pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.

FDA, EMA Recommend Against Starting Olaratumab for Soft Tissue Sarcoma

January 25th 2019

The FDA and European Medicines Agency have recommended that no new patients with advanced soft tissue sarcoma should be treated with the combination of olaratumab plus doxorubicin.

Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial

January 18th 2019

Olaratumab in combination with doxorubicin missed the phase III ANNOUNCE trial’s primary endpoint of overall survival and did not confirm a clinical benefit for patients with advanced or metastatic soft tissue sarcoma compared with standard doxorubicin.

FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices

January 18th 2019

The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.

Novel Strategies Emerging in Uterine Sarcomas

January 17th 2019

Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.

Dr. Ganjoo on Therapies for Patients With Uterine Leiomyosarcomas

November 9th 2018

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses therapies for patients with uterine leiomyosarcomas.

Modern Therapies Expand Options for Soft-Tissue Sarcomas

November 8th 2018

Although soft-tissue sarcoma is seldom diagnosed in adults, the development of several new therapies in recent years for patients with rare subtypes is energizing leaders in the field and underscoring the need for a multidisciplinary approach to care.

Dr. Ganjoo on the Rarity of Uterine Sarcomas

October 31st 2018

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the rarity and diagnosis of uterine sarcomas.

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Dr. Riedel on the Role of Immunotherapy in Uterine Sarcoma

September 19th 2018

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the emerging role of immunotherapy in uterine sarcoma.

More Effective Therapies Needed in Uterine Sarcomas

August 31st 2018

Richard Riedel, MD, discussed the presentation and standard management of uterine sarcomas, the potential role of immunotherapy and targeted agents, and the challenges he hopes to overcome in the landscape in the near future.

Dr. Riedel on the Treatment Landscape of Uterine Sarcomas

August 30th 2018

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the treatment landscape of uterine sarcomas.

Dr. Secord on the Management of Patients With Sarcoma

August 28th 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the management of patients with sarcoma.

Conclusions on Management of Advanced STS

July 12th 2018

Case Study: Stage IV Undifferentiated Pleomorphic Sarcoma

July 12th 2018

Case Study: Recurrent De-Differentiated Liposarcoma

July 12th 2018